Stocks that reacted more will give you more. NVDA the poster child dropped from $437 to $400 in a few days. It is now back to where it was!! You could argue a fast stk like this could give you the entire near $40 drop now to the upside.
STEM I feel can run into it's earnings. MY target for that is $7 1/2 <------------ After earn = $9 1/2
NERV- I missed this news late June i certainly would of pounced-- Minerva Neurosciences Announces $20 Million in Private Placement Priced at a Premium to Market Minerva Neurosciences, Inc June 28, 2023 Minerva Neurosciences, Inc BURLINGTON, Mass., June 28, 2023 (GLOBE NEWSWIRE) --Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it has agreed to sell an aggregate of 1,425,000 shares of its common stock at a purchase price of $10 per share and pre-funded warrants to purchase an aggregate of 575,575 shares of its common stock at a purchase price of $9.99 per pre-funded warrant, to Boehringer Ingelheim, a global biopharmaceutical company with a growing mental health pipeline that includes schizophrenia, and Federated Hermes Kaufmann Funds in a private investment in public equity (the “PIPE”) financing. Minerva expects that the gross proceeds from the PIPE will be approximately $20 million, before deducting PIPE-related expenses payable by Minerva. Minerva intends to use the net proceeds from the PIPE to support potential regulatory approval in the U.S., commercialization activities and market launch of roluperidone, which is being developed for the treatment of negative symptoms in schizophrenia.
Damn was I at the beach? This is highly unusual the stk was $6 and raised cash at $9<-- Hello! when is the last time that happened!!!!! WTF--- This should keep going... we have to research this::::::: STOCK OF THE DAY NERV
BURLINGTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that on May 8, 2023, it received confirmation from the U.S. Food and Drug Administration (FDA) that the Company’s New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia has been filed in accordance with the recent Appeal Granted letter dated April 27, 2023 and assigned a standard review classification. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of February 26, 2024. The FDA advised that it identified potential review issues that had been previously cited in the refuse-to-file decision letter, which included those discussed at the Type C meeting in March 2022. “The filing of the NDA is an important event for Minerva and a step forward to our goal to treat those patients suffering negative symptoms of schizophrenia. If approved, we believe roluperidone could be an important new option to address the serious unmet need faced by that group of patients with schizophrenia whose negative symptoms are a major source of disability and adversely impact their daily quality of life,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. About Roluperidone Roluperidone is an investigational drug that has been shown to block serotonin, sigma and α-adrenergic receptors that are all involved in the regulation of important brain functions, including mood, cognition, sleep, and anxiety. Roluperidone was designed to avoid a direct blockade of dopaminergic receptors (the key pharmacological target for first- and second-generation antipsychotics), while maintaining blockade of a specific subtype of serotonin receptor called 5-HT2A (an additional key target of second-generation antipsychotics) as well as additional pharmacological targets (sigma2 and adrenergic-α1A).
I THINK I MAY HAVE SOMETHING HERE-- > ATEC RESEARCH Medical Technology Stock Breaks Out, Sees 28% Revenue Growth Medical technology stockAlphatec Holdings(ATEC) is a newIBD 50addition and broke out of a base on Monday. The medical technology company designs, develops and makes surgical equipment for spinal surgeries. The company's implanted parts include titanium screws, rods, fusion components and biologics. On April 19, it entered into anAsset Purchase Agreementwith Integrity Implants and Fusion Robotics to acquire assets used in a navigation-enabled robotics platform for $55 million in cash. Alphatec is ranked No. 22 out of 139 stocks in the medical products industry group. The group ranks a strong No. 39 out of the 197 IBD industry groups. Medical product stocks got renewed interest followingUnitedHealth Group's (UNH) June 14 news that seniors are catching up on postponed surgeries. Medical Technology Stock Hits Buy Point ATEC stock popped 8.8% in heavy volumeon Monday, after Lake Street raised its price target to 32 from 20 and maintained its buy rating. Shares broke out of a wide-and-loose base, hitting the 17.13 buy point on Monday in two days of heavy volume. ATEC is in the5% buy zone, which goes up to 17.99. The medical technology stock hit a 52-week high on Tuesday and has gained over 44% this year so far. The relative strength line hit a 52-week high as shown by the blue dot on the MarketSmith daily and weekly charts. ATEC wavered around the5 0-day moving average during most of the base, until pushing decisively above it as the stock rallied in the last week. Management Sees Long-Term Sales Growth Although Alphatec is not yet profitable, annual losses are getting smaller. The company posted mixed first-quarter results on May 4, with a higher-than-expected loss but sales that exceeded analysts' forecasts. Quarterly sales growth accelerated to 54% from 43% in the last two quarters. The growth came from a 40% increase in surgical volume and an 11% increase in average revenue per procedure. The company reiterated its 28% projected total revenue growth to $450 million for full-year 2023. Management alsoreiterated its full-year revenue forecastof $555 million by 2025. It initially provided that outlook during its lastInvestor Day presentation in May 2022. Management gave a 20% long-term revenue growth outlook, and projected positive operating margin and cash flow in 2025. The company has dominated market share, with 50% in 2021, up from 30% in 2020. Alphatec is securing regulatory approvals from Australia and Japan, and expects to enter the Japanese market in 2025, according to the 2022 Investor Day presentation. Management owns a high 17% of the medical technology stock, while mutual funds own 38% of shares. Mutual funds added shares, with 258 funds owning ATEC in March, up from 241 in December and 224 in September. SPOTLIGHT->ATEC-$18.30
ATEC LOOKS LIKE A BIO ON A CHART BUT IT'S MED TECH AND HAS REAL EARNINGS DOWN THE LINE... WE ARE NOT THAT FAR AWAY FROM THE IBD BUY POINT LES THAN 50 CENTS AND THE TA IS FREE AND CLEAR THIS IS GOING LOW $20'S I DON'T KNOW IF THIS IS A GOOD SWAP WITH RELL THEY ARE SO DIFFERENT... I HAVE TO FIT THIS IN SOMEWHERE --> TODAY'S BUY IS ATEC. ... AND THAT'S HOW YOU DO IT FOLKS.YOU WAKE UP EARLY AND YOU STOCK SURF (Tm* stoney) and you find something.